Finasteride is effective for the treatment of central serous chorioretinopathy

E. Moisseiev, A. J. Holmes, Ala Moshiri, Lawrence S Morse

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


PurposeTo evaluate the safety and efficacy of finasteride treatment in patients with central serous chorioretinopathy (CSC).MethodsRetrospective review of 29 eyes of 23 patients who were treated with finasteride for CSC. Previous medical and ocular history, steroid use, length of finasteride treatment, additional treatments for CSC, visual acuity (VA), central macular thickness (CMT), and presence of subretinal fluid (SRF) throughout the follow-up period, and the occurrence of any complications were recorded.ResultsInitial VA was 0.29±0.31 logMAR, and a trend towards improved VA was noted after 3 months (0.25±0.36 logMAR; P=0.07). VA was significantly improved at the final follow-up (0.23±0.27 logMAR; P=0.024). Initial CMT was 354±160 μm, and was significantly reduced after 1 month of treatment (284±77 μm; P=0.002) and this was maintained to the end of follow-up (247±85 μm; P=0.001). A significant reduction in SRF presence was found at all time points, with an overall 75.9% rate of complete resolution. Following discontinuation, SRF recurrence was noted in 37.5% of cases. No adverse events were recorded.ConclusionsFinasteride is a safe and effective treatment for CSC. It may be a possible new option for the initial management of patient with CSC, and a suggested treatment approach is presented.

Original languageEnglish (US)
Pages (from-to)850-856
Number of pages7
JournalEye (London, England)
Issue number6
StatePublished - Jun 1 2016

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Finasteride is effective for the treatment of central serous chorioretinopathy'. Together they form a unique fingerprint.

Cite this